---
title: "Michael Okunewitch Initiates Buy on Evaxion, Citing Strong Clinical Data, AI-Driven Vaccine Platform, and Cash Runway to 2H 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285777716.md"
description: "Maxim Group analyst Michael Okunewitch has initiated a Buy rating on Evaxion (EVAX), citing strong clinical data, an AI-driven vaccine platform, and a cash runway extending to the second half of 2027. He highlights promising results from recent AACR presentations and the company's partnerships with major players like Merck and the Gates Foundation. Lake Street also maintains a Buy rating with a $9.00 price target. However, EVAX's stock has seen a 36.21% decline over the past six months, dropping from $6.38 to $4.07."
datetime: "2026-05-08T21:15:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285777716.md)
  - [en](https://longbridge.com/en/news/285777716.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285777716.md)
---

# Michael Okunewitch Initiates Buy on Evaxion, Citing Strong Clinical Data, AI-Driven Vaccine Platform, and Cash Runway to 2H 2027

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on EVAX stock, giving a Buy rating today.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Michael Okunewitch has given his Buy rating due to a combination of factors, including encouraging clinical data and a solid financial runway. He points to Evaxion’s recent AACR presentations, where EVX-01 in advanced melanoma showed a high rate of newly formed, tumor-specific T-cell responses, supporting the potential for durable clinical benefit, while early data in glioblastoma suggest the platform could tackle notoriously resistant, immune-cold tumors.

He also highlights the company’s proprietary AI-Immunology engine, which can rapidly and cheaply identify vaccine targets, enabling a growing pipeline spanning oncology, infectious disease, and future autoimmune indications. In addition, strategic partnerships with major players such as Merck and the Gates Foundation, progress of next-wave programs like EVX-04, and cash expected to fund operations into the second half of 2027 collectively underpin his constructive outlook on the shares.

In another report released today, Lake Street also maintained a Buy rating on the stock with a $9.00 price target.

EVAX’s price has also changed moderately for the past six months – from $6.380 to $4.070, which is a -36.21% drop .

### Related Stocks

- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | EVAX Stock News](https://longbridge.com/en/news/286109610.md)
- [Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial | EVAX Stock News](https://longbridge.com/en/news/283185262.md)
- [1 unstoppable stock to buy before it joins Nvidia, Alphabet, and Apple in the $4 trillion club](https://longbridge.com/en/news/286480754.md)
- [AI momentum and earnings strength fuel Wall Street rally](https://longbridge.com/en/news/286506652.md)
- [ZAWYA: Enterprise AI hits the wall: NTT DATA research reveals growing privacy and sovereignty barriers](https://longbridge.com/en/news/286511415.md)